![]() |
市场调查报告书
商品编码
1319148
全球数字病理市场 - 2023-2030 年Global Digital Pathology Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
全球数字病理市场规模在 2022 年达到 9 亿美元,预计到 2030 年将实现利润丰厚的增长,达到 17 亿美元。在预测期内(2023-2030 年),全球数字病理市场预计将呈现 8.7% 的复合年增长率。远程病理学和远程会诊的日益普及推动了数字病理学市场需求的增长趋势。
数字病理学市场正经历着显著的增长和转型。数字病理学涉及病理图像的数字化和管理,使病理学家能够以电子方式访问和分析切片。这项技术具有众多优势,包括提高工作流程效率、加强协作、准确诊断,以及与人工智能(AI)算法进行潜在整合以实现自动分析。
推动全球数字病理市场发展的因素包括:慢性病发病率不断上升、人工智能(AI)的整合、越来越多地采用数字病理技术提高实验室效率、数字病理系统的技术进步、老年人口不断增加以及数字病理技术在辅助诊断和药物开发中的应用日益增多。
传统的病理操作需要使用玻璃载玻片,这些载玻片需要人工处理、存储和运输。这一过程既耗时又容易出错。数字病理学无需使用实体玻片,病理学家可远程访问和分析图像。这提高了工作流程效率,缩短了周转时间,并提高了实验室的整体生产率。
数字病理学还能促进病理学家之间的无缝协作。无论身处何地,都能轻松共享图像、进行远程会诊和提供第二意见。病理学家可以实时协作,从而做出更准确的诊断,改善患者的治疗效果。此外,数字病理学还能整合人工智能(AI)和机器学习算法进行自动分析,进一步提高效率和准确性。
例如,2023 年 6 月 19 日,阿联酋最大的医院之一、阿布扎比医疗服务公司(SEHA)与梅奥诊所的合资企业谢赫-沙赫布特医疗城(SSMC)启动了其最先进的病理实验室,该实验室将支持 SSMC 专家领导的病理团队利用人工智能工具和应用,最准确地诊断疾病和复杂病症。
辅助诊断包括使用诊断测试来识别可能对特定治疗方法产生反应的患者。数字病理学通过分析组织样本和生物标记物来确定患者是否符合接受靶向治疗的条件,在辅助诊断中发挥着至关重要的作用。数字病理平台可对基因突变或蛋白质表达等生物标志物进行准确、标准化的评估,这对指导治疗决策至关重要。
数字病理学还为药物开发和研究做出了重大贡献。它使制药公司和研究人员能够分析潜在候选药物对组织样本的影响。数字病理平台为临床前和临床试验期间评估新药的疗效和安全性提供了标准化和可重复的方法。
通过自动图像分析和利用人工智能算法,数字病理学可帮助识别和量化药物治疗引起的细胞和分子变化。这加快了药物开发过程,有助于就新疗法的有效性和安全性做出明智决策。
例如,2023 年 6 月 22 日,高分辨率定量数字病理学和人工智能领域的领先企业 PharmaNest Inc 宣布推出其数字病理学空间分辨定量组织面板,用于描述纤维化情况下组织损伤和炎症的严重程度,并允许对纤维化情况下的炎症进行新型人工智能驱动的研究,适用于从发现模型到临床开发的任何情况。
数字病理学仍在不断发展,在图像格式、元数据和分析算法等各个方面都缺乏标准化。缺乏标准化协议和指南会给不同平台和机构之间的数据共享、比较和可重复性带来挑战。为克服这些挑战,有必要努力实现标准化并在利益相关者之间开展合作。
COVID-19 大流行对数字病理学市场产生了重大影响。大流行导致必须采取社会隔离措施,减少人际交往,从而使远程诊断和远程病理学变得至关重要。数字病理学使病理学家能够远程访问和分析病理图像,从而在最大程度降低病毒传播风险的同时继续提供诊断服务。大流行期间,对远程会诊和远程病理解决方案的需求激增,推动了数字病理系统的采用。
据估计,俄乌冲突对全球数字病理学市场的影响不大。由于冲突,数字病理学领域的国际合作和研究计划可能面临中断。这可能会影响联合项目的进展以及知识和资源的共享,从而可能减缓全球数字病理学市场的创新和进步。
The global digital pathology market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.7 billion by 2030. The global digital pathology market is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030). The increasing adoption of telepathology and remote consultation is driving up demand for digital pathology market trends.
The digital pathology market is experiencing significant growth and transformation. Digital pathology involves the digitization and management of pathology images, enabling pathologists to access and analyze slides electronically. This technology offers numerous advantages, including improved workflow efficiency, enhanced collaboration, accurate diagnosis, and potential integration with artificial intelligence (AI) algorithms for automated analysis.
The global digital pathology market is driven by the factors such as the increasing prevalence of chronic diseases, integration of artificial intelligence(AI), increasing adoption of digital pathology to enhance lab efficiency, technological advancements in digital pathology systems, the rising geriatric population, and increasing applications of digital pathology in companion diagnostics and drug development.
Traditional pathology practices involve the use of physical glass slides that require manual handling, storage, and transportation. This process can be time-consuming and prone to errors. Digital pathology eliminates the need for physical slides and enables pathologists to access and analyze images remotely. This enhances workflow efficiency, reduces turnaround times, and improves the overall productivity of the laboratory.
Digital pathology also facilitates seamless collaboration among pathologists. It allows for easy sharing of images, remote consultations, and second opinions, regardless of geographical location. Pathologists can collaborate in real time, leading to more accurate diagnoses and improved patient outcomes. Moreover, digital pathology enables the integration of artificial intelligence (AI) and machine learning algorithms for automated analysis, further enhancing efficiency and accuracy.
For instance, on June 19, 2023, Sheikh Shakhbout Medical City (SSMC), one of the UAE's largest hospitals and a joint-venture partnership between Abu Dhabi Health Services Company (SEHA) and Mayo Clinic, launched its state-of-the-art, Pathology Laboratory, which will support SSMC's expert-led pathology team in diagnosing disease and complex conditions with the utmost accuracy using AI-powered tools and applications.
Companion diagnostics involves using diagnostic tests to identify patients who are likely to respond to a specific therapeutic treatment. Digital pathology plays a crucial role in companion diagnostics by enabling the analysis of tissue samples and biomarkers to determine a patient's eligibility for targeted therapies. Digital pathology platforms provide an accurate and standardized assessment of biomarkers such as genetic mutations or protein expression, which are essential for guiding treatment decisions.
Digital pathology is also making significant contributions to drug development and research. It allows pharmaceutical companies and researchers to analyze the effects of potential drug candidates on tissue samples. Digital pathology platforms offer a standardized and reproducible method for assessing the efficacy and safety of new drugs during preclinical and clinical trials.
By automating image analysis and leveraging AI algorithms, digital pathology assists in identifying and quantifying cellular and molecular changes induced by drug treatments. This accelerates the drug development process and aids in making informed decisions regarding the efficacy and safety of new therapies.
For instance, on June 22, 2023, PharmaNest Inc, a leader in high-resolution quantitative Digital Pathology and Artificial Intelligence, announced the launch of its Digital Pathology spatially resolved, quantitative tissue panels to describe the severity of tissue injury and inflammation in the context of fibrotic conditions and allow novel AI-driven investigations of inflammation in the context of fibrosis for any condition, from discovery models to clinical development.
Digital pathology is still evolving, and there is a lack of standardization in various aspects, including image formats, metadata, and analytical algorithms. The absence of standardized protocols and guidelines can create challenges in data sharing, comparison, and reproducibility across different platforms and institutions. Efforts towards standardization and collaboration among stakeholders are necessary to overcome these challenges.
The COVID-19 pandemic significantly impacted the digital pathology market. The pandemic necessitated social distancing measures and reduced in-person interactions, making remote diagnosis and telepathology essential. Digital pathology enabled pathologists to remotely access and analyze pathology images, allowing for continued diagnostic services while minimizing the risk of virus transmission. The demand for remote consultation and telepathology solutions surged during the pandemic, driving the adoption of digital pathology systems.
The Russia-Ukraine conflict is estimated to have a moderate impact on the global digital pathology market. International collaborations and research initiatives in the field of digital pathology could face disruptions due to the conflict. This may affect the progress of joint projects and the sharing of knowledge and resources, potentially slowing down innovation and advancements in the global digital pathology market.
The global digital pathology market is segmented based on product, application, type, technology, end-user, and region.
Digital pathology software offers advanced image analysis tools that assist pathologists in quantifying and analyzing tissue samples. These tools can automate certain tasks, such as cell counting, measuring biomarker expression, and identifying specific cellular structures. This enhances the efficiency and accuracy of diagnosis, reducing the reliance on manual analysis.
Software platforms in digital pathology increasingly integrate AI capabilities for automated analysis and pattern recognition. AI algorithms can assist in identifying anomalies, predicting disease outcomes, and providing decision support to pathologists. This integration enhances efficiency, accuracy, and consistency in diagnosis and allows for the discovery of new biomarkers and therapeutic targets.
Digital pathology software provides robust data management and storage capabilities. It enables the creation of centralized repositories for pathology images, patient data, and associated metadata. These repositories serve as valuable resources for research, quality assurance, and educational purposes. Software solutions ensure secure storage, retrieval, and sharing of digital pathology data while adhering to data protection regulations.
For instance, on June 8, 2023, Indica Labs announced the launch of a service offering deployment and ongoing support of its HALO digital pathology software in a fully managed cloud-hosted environment powered by Amazon Web Services (AWS). The service enables organizations to benefit from Indica Labs' software development and cloud deployment expertise while maintaining full ownership and control over their AWS account. Indica Labs' entire suite of HALO software, including the HALO Image Analysis platform, HALO AI deep learning classifier add-on, HALO Link browser-based image management system, and HALO AP anatomic pathology workflow platform, can now be deployed in professionally managed AWS cloud-hosted environments.
North America boasts a well-developed and advanced healthcare infrastructure, including hospitals, diagnostic laboratories, and research institutions. The region has made significant investments in healthcare technologies, including digital pathology, to enhance patient care and diagnostic capabilities. The availability of state-of-the-art facilities and resources facilitates the adoption and implementation of digital pathology systems.
North America is home to several major players in the digital pathology market, including technology providers, software developers, and research organizations. These companies have made substantial investments in research and development, driving technological advancements and innovation in the field. The presence of established players with strong market positions contributes to the overall market growth and dominance of North America.
For instance, in September 2022, INFINITT North America, an award-winning developer of enterprise imaging solutions for healthcare, announced a collaboration with Hamamatsu Corporation to jointly promote Hamamatsu whole slide scanners (NanoZoomers) and INFINITT Digital Pathology Solution (IDPS) to its United States customers.
The major global players in the digital pathology market include: F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., Olympus Corporation, Leica Biosystems Nussloch GmbH (Danaher Corporation), Hamamatsu Photonics, Inc., Mikroscan Technologies, Inc., Inspirata, Inc. (Fujifilm), Visiopharm A/S, Huron Technologies International Inc., and ContextVision AB.
The global digital pathology market report would provide approximately 53 tables, 54 figures, and 195 Pages.
LIST NOT EXHAUSTIVE